Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies.
| dc.contributor.author | Evans, D G | |
| dc.contributor.author | Harkness, E | |
| dc.contributor.author | Lalloo, F | |
| dc.contributor.author | Howell, Anthony | |
| dc.date.accessioned | 2014-09-04T09:10:51Z | |
| dc.date.available | 2014-09-04T09:10:51Z | |
| dc.date.issued | 2014-07-22 | |
| dc.identifier.citation | Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies. 2014: J Med Genet | en |
| dc.identifier.issn | 1468-6244 | |
| dc.identifier.pmid | 25053764 | |
| dc.identifier.doi | 10.1136/jmedgenet-2014-102336 | |
| dc.identifier.uri | http://hdl.handle.net/10541/325849 | |
| dc.description.abstract | The risks of breast cancer associated with BRCA1 and BRCA2 mutations vary considerably across studies but few have assessed prospective risks, which are likely to provide more reliable risk estimates for women undergoing presymptomatic testing. | |
| dc.language | ENG | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Journal of medical genetics | en |
| dc.title | Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies. | en |
| dc.type | Article | en |
| dc.contributor.department | Genesis Breast Cancer Prevention Centre, University Hospital of South Manchester NHS Trust, Manchester, UK Manchester Centre for Genomic Medicine, Central Manchester Foundation Trust, St. Mary's Hospital, Manchester, UK Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester, Christie Hospital, Manchester, UK The University of Manchester, Manchester Academic Health Science Centre, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK. | en |
| dc.identifier.journal | Journal of Medical Genetics | en |
| html.description.abstract | The risks of breast cancer associated with BRCA1 and BRCA2 mutations vary considerably across studies but few have assessed prospective risks, which are likely to provide more reliable risk estimates for women undergoing presymptomatic testing. |